Abstract

Introduction

During the SARS-CoV-2 pandemic, intensive care units (ICUs) were pivotal in treating severe cases. In the ICU, invasive procedures and the use of immunosuppressive drugs have been associated with an increased risk of infection. To compare the antibiotic use, infection types, culture positivity, and resistance patterns among patients in the intensive care unit during and after the pandemic.

Materials and Methods

The patients who were followed up in the adult ICU at our hospital were retrospectively assessed after being divided into two groups. Group 1 included patients admitted between December 1, 2020, and January 5, 2021, (pandemic group). Group 2 consisted of patients admitted between June 1, 2021, and November 1, 2023 (post-pandemic).

Results

Antimicrobial (100% vs. 93.3%, p = 0.004), antibiotic (100% vs. 92.7%, p = 0.003), and antifungal (33.3% vs 10.7%, p < 0.001) use was higher during the pandemic than after the pandemic. Additionally, multiple classes of antimicrobial drugs were used and antivirals were administered more commonly during the pandemic than after the pandemic (p < 0.001). The interval from admission to antimicrobial therapy, duration of antimicrobial therapy, and total length of hospital stay were statistically longer during the pandemic than after the pandemic. The culture-positive endotracheal aspirates (ETAs) were more frequently observed during the pandemic than after it (56% vs. 42.1%, p = 0.019). The proportion of patients in whom Klebsiella spp. were identified in the ETA was higher during the pandemic than after the pandemic (19.1% vs. 7.3%). Furthermore, the blood cultures yielded the growth of Stenotrophomonas maltophilia, Klebsiella spp.,and Candida spp. more commonly in the pandemic group than in the post-pandemic period.

There was no statistically significant difference in the proportion of patients who developed methicillin-resistant Staphylococcus aureus infection (p = 0.473), methicillin-resistant coagulase-negative Staphylococcus infection (p = 0.263), or third-generation cephalosporin-resistant (p = 0.658) and carbapenem-resistant Gram-negative infections (p = 0.214) between the two time periods.

Conclusion: In our study, a notable disparity was observed in the antibiotic usage rates and types between the two study groups. We hypothesize that this discrepancy may be attributed to the rigorous implementation of infection control measures and the enhanced effectiveness of the antibiotic stewardship committee, particularly during and following the period of reduced epidemic incidence.

Keywords:

COVID-19, intensive care unit, antimicrobials, infection

Introduction

Infections in intensive care units (ICUs) are often caused by more resistant agents than those in other hospital areas, posing serious consequences with an increased frequency. Factors contributing to this heightened risk include endotracheal intubation or tracheostomy for mechanical ventilation and frequent invasive procedures such as intravenous or bladder catheterization ^[1].

Infections in ICUs can result in extension of hospital stay, increase in costs, and increase in mortality risk. Furthermore, the potential for the spread of infections originating in ICUs poses a threat to other patients ^{[2, 3, 4]}.

SARS-CoV-2, a novel strain of coronavirus, has been globally spreading since December 2019, leading to the COVID-19 pandemic. Although the clinical course is generally self-limiting, approximately 5% of patients experience severe respiratory failure. Thus, ICUs are pivotal in the treatment of severe cases of COVID-19 requiring respiratory support.

Both invasive procedures (e.g., intubation and catheterization) and the use of steroids and immunomodulatory agents (e.g., tocilizumab) during the disease have been associated with an increased risk of infections ^[5]. The most common bacterial complications of COVID-19 infection include secondary pneumonia, including ventilator-associated pneumonia (VAP), and bloodstream infections (BSI) ^[5].

Due to the high risk of secondary infections, antibiotics are frequently administered to patients in ICUs. Approximately 43% of patients are treated with inappropriate antibiotics, leading to the emergence of resistant agents ^[6]. This increases the risk of secondary bacterial infections in viral epidemics, which was also observed in and contributed to the increased use of antibiotics during the COVID-19 pandemic ^[7].

In this study, we aimed to compare the pandemic period with the post-pandemic period in terms of the characteristics of the infections and antimicrobials used among patients admitted to the ICU.

Methods

Patients who were followed up in the adult ICUs at XXX hospital, which houses 815 beds and 105 ICU beds, were retrospectively assessed after being divided into two groups. Group 1 included patients admitted between December 01, 2020, and May 01, 2021 (during the COVID-19 pandemic), and Group 2 included patients admitted between June, 06, 2021, and November 01, 2023 (post-pandemic). The following data, spanning the 5-month periods, were obtained from the hospital’s electronic database: patient demographics (e.g., age, sex, and underlying comorbidities), infection types, antimicrobials used empirically or targeted therapy for infections, cultured agents and their resistance patterns, length of stay in the ICU, and clinical outcomes. Patients who had consumed prophylactic antibiotics and had a positive SARS-CoV-2 test were not included in the study. Antibiotic use was calculated on the basis of the number of days a patient was hospitalized in the ICU. The study was approved by the Ethics Committee of Istanbul Medeniyet University, City Hospital (No: 2021/0111; |date|), and the study was conducted in accordance with the principles of the Declaration of Helsinki.

Statistical analysis:

Descriptive statistics are presented as numbers and percentages (n, %), mean ± standard deviation (SD), or median with its 25%–75% percentile. Normality was assessed using histograms and the Shapiro–Wilk test. In the comparison of the pandemic and post-pandemic groups, we used the Mann–Whitney U test for non-normally distributed continuous variables and the chi-square or Fisher’s exact test for categorical variables. A p-value < 0.05 was considered statistically significant. R (version 4.2.3; https://www.r-project.org/) was used for all statistical analyses.

Results

The mean age of the study patients was 65.0 ± 16.5 years, and 154 patients (48.3%) were female. Patients in the pandemic group were younger than those in the post-pandemic group (62.5 ± 13.2 vs. 67.1 ± 18.5, p = 0.011). The median delay between symptom onset and hospital admission was longer in the pandemic group than in the post-pandemic group (6 days vs. 2 days, p < 0.001). All the patients in the pandemic group (n = 141) received antimicrobial therapy. Empiric antibiotic therapy was initially administered. Subsequently, the antibiotics were revised according to the culture results. Antimicrobials (100% vs. 93.3%, p = 0.004), antibiotics (100% vs. 92.7%, p = 0.003), and antifungals (33.3% vs. 10.7%, p < 0.001) were used more in the pandemic group than in the post-pandemic group. Additionally, multiple classes of antimicrobials were used more commonly in the pandemic group than in the post-pandemic group (p < 0.001). Among the patients who received antimicrobial therapy (n = 307), the time from admission to antimicrobial therapy (median 6 days vs. 2 days, p < 0.001), duration of antimicrobial therapy (median 17 days vs. 11 days, p < 0.001), and length of hospital stay (median 18 days vs. 11 days, p < 0.001) were statistically significantly longer in the pandemic group than in the post-pandemic group. There was no difference in the end-of-treatment mortality between the two groups (Table 1). Table 2 shows the comparison of the antibiotic classes that were used in the pandemic and post-pandemic groups. Penicillin (68.1% vs. 51.1%, p = 0.003) and cephalosporin (71.6% vs. 40.4%, p < 0.001) group of antibiotics were used more commonly in the pandemic group than in the post-pandemic group. Furthermore, linezolid (51.1% vs. 20.8%, p < 0.001) and tigecycline (39.0% vs. 23.0%, p = 0.003) were used more frequently in the pandemic group than in the post-pandemic group. The polymyxin (30.5% vs. 19.1%; p = 0.026) and aminoglycoside (24.8% vs. 10.7%; p = 0.001) group of antibiotics were used statistically significantly more in the pandemic group than in the post-pandemic group. Furthermore, clindamycin was used more frequently in the pandemic group than in the post-pandemic group (24.8% vs. 7.8%, p < 0.001). Antivirals were used more in the pandemic group than in the post-pandemic group (p < 0.001). The positivity rate of the endotracheal aspirate cultures was high among patients in the pandemic group than among those in the post-pandemic group (56% vs. 42.1%, p = 0.019). However, the positivity rate of urine cultures was higher in the post-pandemic group than in the pandemic group (40.4% vs. 28.4%, p = 0.033). The proportion of patients in whom Klebsiella spp. was identified in the endotracheal aspirate cultures was higher in the pandemic group than in the post-pandemic group (19.1% vs. 7.3%). Stenotrophomonas maltophilia, Klebsiella spp., and Candida spp. were identified in the blood cultures more frequently in the pandemic group than in the post-pandemic group (Table 3).

Table 4 shows the comparison of the resistance patterns of the isolated microorganisms in the pandemic and post-pandemic groups. There was no statistically significant difference in the proportion of patients with methicillin-resistant Staphylococcus aureus (MRSA) infection (p = 0.473), methicillin-resistant coagulase-negative Staphylococcus infection (p = 0.263), or third-generation cephalosporin-resistant (p = 0.658) and carbapenem-resistant Gram-negative infections (p = 0.214) between the two groups.

Empirical antifungal therapy was administered to patients in whom fungal infection was suspected, and the antifungal was revised according to the culture results. Five patients in the pandemic group developed fluconazole-resistant fungal infections. No fungal infections were observed in the post-pandemic group (p = 0.016).

All patients in the pandemic group who were admitted to the ICU and 25 patients in the post-pandemic group (n = 178) were administered steroid therapy. In the pandemic group, 54, 15, 3, 4, 60, and 5 patients developed bacterial pneumonia, bacteremia/sepsis, urinary tract infection, candidemia, viral pneumonia, and other infections, respectively. In the post-pandemic group, 48, 44, 32, 4, and 50 patients were diagnosed with bacterial pneumonia, bacteremia/sepsis, urinary tract infection, candidemia, and other infections, respectively. In the pandemic group, the rates of VAP, catheter-associated BSI, and urinary catheter-associated infections (CAUTI) in the ICU were 1, 3, and 1, respectively. In the post-pandemic group, 1 patient developed VAP, 13 developed BSI, and 4 developed CAUTI.

Discussion

In our study, we observed a higher consumption of antimicrobials in patients hospitalized in ICUs during the pandemic period than in those hospitalized during the post-pandemic period. Furthermore, we observed an increase in the use of multiple antibiotics, longer duration of antibiotic use, and longer hospital stay in the pandemic period than in the post-pandemic period.

Approximately 70% of patients admitted to the ICU are administered prophylactic, preemptive, empirical, or targeted antibiotic therapy. However, up to 30% of patients treated with antibiotics in the ICU do not have an active infection ^[8]. An analysis of antibiotic use revealed notable factors such as unnecessary combination therapy involving two or more antibiotics, prolonged prophylaxis, or extended antibiotic treatment beyond the recommended periods ^[8]. The challenge of diagnosing infections in patients admitted to the ICU also reportedly contributes to inappropriate antibiotic use.

Although routine antibiotic use was not recommended during the COVID-19 pandemic, studies conducted in various countries, including our own ^{[6, 7, 8, 9, 10, 11, 12]}, have reported an increase in antibiotic use during this period. In patients admitted to the ICU, antibiotics that were started prophylactically/empirically were revised according to the culture results. In our study, we observed a significant increase in the use of antibiotic (ceftriaxone, linezolid, tetracycline, and clindamycin), antifungal, and antiviral drugs during the pandemic than during the post-pandemic period. A study conducted in Egypt revealed an increase in the use of carbapenem, vancomycin, linezolid, trimethoprim-sulfamethoxazole, and azithromycin, as well as a decrease in the use of fluoroquinolones, lincosamides, and third- and fourth-generation cephalosporins in ICUs during the COVID-19 period ^[13].

Malik et al. reported that antibiotics were administered to 78% of the patients during the COVID-19 period, with ceftriaxone and azithromycin being the most commonly administered antibiotics ^[14]. Similarly, Grau et al. found an increase in the antibiotic use in Spain during the first wave of the COVID-19 pandemic ^[15]. Meta-analysis studies on antibiotic use during the COVID-19 period revealed usage rates ranging from 72% to 75%, with coinfection rates ranging from 3.5% to 8.6% ^[16]. At the onset of the COVID-19 pandemic, factors such as uncertainty regarding the disease’s treatment, overwhelmed hospitals, inadequate functioning of antibiotic control committees, shortage of physicians dedicated to COVID-19, observations of secondary bacterial infections in previous epidemics, and the initial recommendation for broad-spectrum antibiotic use in patients admitted to the ICU contributed to the excessive and inappropriate use of antibiotics ^{[14, 15, 16, 17]}.

In Turkey, Menekse et al. reported that antibiotics were administered to 91% of the patients admitted to the ICU due to COVID-19, and the most commonly used antibiotics were piperacillin-tazobactam, carbapenems, tigecycline, and methicillin-resistant Gram-positive resistant groups ^[18]. In our study, although there was no difference between the two periods in the use of carbapenems and tigecycline, there was a significant increase in the use of linezolid during the pandemic.

ICUs represent environments where nosocomial infections are most frequently encountered. In a meta-analysis study, the rate of secondary infections in patients hospitalized in ICUs due to COVID-19 ranged from 7% to 51%. Pneumonia was identified as the most common secondary infection, with Gram-negative bacteria, primarily Pseudomonas aeruginosa, Enterobacter spp., and Escherichia coli, emerging as the predominant causative agents ^{[3, 19, 20]}.

In our study, the interval between symptom onset, hospital admission, and initiation of antibiotic therapy was significantly longer in the pandemic group than in the post-pandemic group. Pneumonia was the most prevalent infection during this time, as evidenced by the increased number of tracheal aspirate cultures and significantly extended intubation durations. In the post-pandemic period, the most common infections were bacterial pneumonia, sepsis/bacteremia, and urinary tract infections, in that order. The absence of a significant difference in mortality between the two periods in our study may be attributed to the consistent profiles of infectious agents and antimicrobial resistance across both periods.

In our study, no significant difference was observed in the types of infectious agents isolated from the patients admitted to the ICU during and after the pandemic. Blood cultures revealed comparable rates of methicillin-resistant coagulase-negative Staphylococci, MRSA, carbapenem-resistant Gram-negative bacteria, and cephalosporin-resistant Gram-negative agents across both time periods (Table 3). However, endotracheal aspirate cultures were more prevalent during the pandemic than after the pandemic (56% vs. 42.1%, p = 0.019). Conversely, positive urine cultures were more frequently identified after the pandemic than during the pandemic (40.4% vs. 28.4%, p = 0.033).

During the pandemic, Klebsiella spp. and Stenotrophomonas maltophilia were the most commonly identified causative agents of pneumonia in tracheal aspirate cultures. In the post-pandemic period, nosocomial infections were predominantly caused by Gram-negative bacteria, particularly Acinetobacter and Pseudomonas species. Similar findings were reported by Da Costa et al., who identified Acinetobacter baumannii, P. aeruginosa, and Klebsiella pneumoniae as the most common agents causing secondary infections in patients with COVID-19 who were admitted to the ICU ^[21]. Chen et al. observed that community-acquired pathogens such as Mycoplasma, Haemophilus influenzae, and Streptococcus pneumoniae were the most common causes of secondary infections in patients with mild and moderate diseases. However, nosocomial pathogens such as S. maltophilia, K. pneumoniae, P. aeruginosa, and Enterobacter aerogenes were the most common cause of secondary infection in patients with critical and severe diseases ^[22]. These findings are consistent with those of our study.

In a study from the Czech Republic that compared nosocomial infection agents before and during the pandemic, a significant decrease in E. coli, Proteus mirabilis, and S. aureus was observed during the pandemic ^[23]. However, infections due to Enterococcus faecium, Klebsiella variicola, and Serratia marcescens were higher in the pre-pandemic period ^[23].

Limitations

The primary limitation of our study lies in its retrospective nature. Furthermore, it was a single-center study that evaluated the most common infections. Furthermore, the antibiotic consumption rate was calculated according to the day of treatment rather than the WHO standard.

Conclusion

In our study, although there was no statistically significant difference in the microbiological agents detected in the cultures between both time periods, there was a notable difference in the rates and types of antibiotics administered. This suggests that certain antibiotics were initially overutilized at the onset of the pandemic, which may have been due to their anticipated effectiveness against the virus. We propose that this disparity may be attributed to the rigorous implementation of infection control measures and the enhanced efficacy of the antibiotic stewardship committee, particularly during and following the period when the epidemic rate declined.

The study protocol was approved by the Ethics Committee of Istanbul Medeniyet University, City Hospital and the study was conducted in accordance with the principles of the Helsinki Declaration (Ethics committee no: 2021/0111).

Conclusion

References

UNAIDS. Fact Sheet 2022. Last Accessed Date: 2022 Jan 13. Available from:https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

Republic of Turkey, Ministry of Health. HIV-AIDS İstatistikleri. Last Accessed Date: 2022 Sep 13. Available from:https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastaliklar-ve-erken-uyari-db/Dokumanlar/Istatistikler/hiv-aids-2023.pdf

Carballo E. UNAIDS Global HIV Statistics. Last Accessed Date: 2022 Jan 13. Available from:https://www.unaids.org/en/resources/fact-sheet

Cooper V, Clatworthy J, Harding R, Whetham J. Emerge Consortium. Measuring quality of life among people living with HIV: a systematic review of reviews. Health Qual Life Outcomes. 2017;15:220.

Pedersen KK, Eiersted MR, Gaardbo JC, Pedersen M, Gerstoft J, Troseid M, Nielsen SD. Lower Self-Reported Quality of Life in HIV-Infected Patients on cART and With Low Comorbidity Compared with Healthy Controls. J Acquir Immune Defic Syndr. 2015;70:16-22.

Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, Anderson J, Collins S, Hart G, Sherr L, Lampe FC. ASTRA (Antiretrovirals, Sexual Transmission and Attitudes) Study: Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1:32-40.

Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, Gatell JM, Baptista-Leite R, Mendão L, Porter K, Vella S, Rockstroh JK. Beyond viral suppression of HIV–the new quality of life frontier. BMC Med. 2016;14:1-5.

World Health Organization. Measuring quality of life: the development of the World Health Organization Quality of Life Instrument (WHOQOL). Geneva. 1993.

Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality-of-life claims for labeling and promotion. Value Health. 1999;2:113-27.

Bowling A. Measuring disease: A review of disease-specific quality of life measurement scales. 2nd ed. Berkshire: Open University Press; 2001.

Popping S, Kall M, Nichols BE, Stempher E, Versteegh L, van de Vijver DAMC, van Sighem A, Versteegh M, Boucher C, Delpech V, Verbon A. Quality of life among people living with HIV in England and the Netherlands: a population-based study. Lancet Reg Health Eur. 2021;8:100177.

Kall M, Fresán U, Guy D, Brown G, Burgui C, Castilla J, Grecu VI, Dumitrescu F, Delpech V, Lazarus JV. Quality of life in people living with HIV in Romania and Spain. BMC Infect Dis. 2021;21(Suppl 2):898.

Erdinc FS, Dokuzoguz B, Unal S, Komur S, Inkaya AC, Inan D, Karaoglan I, Deveci A, Celen MK, Kose S, Erben N, Senturk GC, Heper Y, Kutlu SS, Hatipoglu CA, Sumer S, Kandemir B, Sirmatel F, Bayindir Y, Yilmaz E, Ersoy Y, Kazak E, Yildirmak MT, Kayaaslan B, Ozden K, Sener A, Kara A, Gunal O, Birengel S, Akbulut A, Yetkin F, Cuvalci NO, Sargin F, Pullukcu H, Gokengin D, Multicentric Hiv Study Group. Temporal Trends in the Epidemiology of HIV in Turkey. Curr HIV Res. 2020;18:258-66.

Gokengin D, Tabak F, Korten V, Lazarus JV, Unal S. The HIV Treatment Cascade in Turkey. HepHIV 2019 Bucharest Conference: Challenges of Timely and Integrated Testing and Care. 2019;P04/09. Available from:https://eurotest.org/media/usumqenv/po4_09.pdf

Gokengin D, Cimen C, Cagatay A, Gencer S, Akalin H, Ceran N, Deveci A, Ozdemir H, Erdinc S, Dogan G, Korten V. HIV cascade of care in Turkey: Data from the HIV-TR cohort. HIV Med. 2019;20:112-3.

Kuman Tunçel Ö, Pullukçu H, Erdem HA, Kurtaran B, Taşbakan SE, Taşbakan M. COVID-19-related anxiety in people living with HIV: an online cross-sectional study. Turk J Med Sci. 2020;50:1792-800.

Karacaer Z, Altındiş S, Gencer S, Gümüşer F, Erol S, Özkan H, Öztürk S, Birengel S, Parlak E, Yalçı A, Ağalar C, Tosun S, Altındiş M. Quality of life in people living with human immunodeficiency virus: A cross-sectional study. Klimik Derg. 2019;32:154-60.

Atalay S, Ucak HA, Ascibasi K, Sonmez U. Quality of Life of People Living with HIV Compared with that of The General Population in Turkey: A Cross Sectional Study. PBS. 2022;12:32-40.

Demirel OF, Mayda PY, Yıldız N, Sağlam H, Koçak BT, Habip Z, Kadak MT, Balcıoğlu İ, Kocazeybek B. Self-stigma, depression, and anxiety levels of people living with HIV in Turkey. Eur J Psychiat. 2018;32:182-6.

Ergen P, Görmez A, Ankaralı H, Aydın Ö, Baysal NB, Çağ Y. Anxiety and Depression among People Living with HIV During the COVID-19 Pandemic: A Face-to-Face Survey from Turkey. Psychiatr Danub. 2023;35:103-11.

Aşçıbaşı K, Albayrak Uçak H, Atalay S, Sönmez U. Depressive and Anxiety Symptoms Among People Living with HIV in Turkey: A Cross-sectional Study. J Tepecik Educ Res Hosp. 2022;32:63-72.

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-83.

Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality‐of‐life instruments. Pharmacoeconomics. 2000;17:13-35.

Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.1. Health Qual Life Outcomes. 2007;5:54.

Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171-8.

Hikasa S, Shimabukuro S, Hideta K, Kuroda N, Higasa S, Sawada A, Tokugawa T, Ikegami A, Kotani A, Kimura T. Quality of life of people living with HIV compared with that of the general population in Japan. J Infect Chemother. 2017;23:698-702.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.

Hisli N. Beck Depresyon Envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji Dergisi. 1989;7:3-13.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-7.

Ulusoy M. Beck Anksiyete Ölçeğinin Psikometrik Özellikleri [dissertation]. Istanbul: Bakırköy Hospital for Mental Disorders; 1993.

Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio, TX: Psychological Corp. 1993.

Bekele T, Rourke SB, Tucker R, Greene S, Sobota M, Koornstra J, Monette L, Rueda S, Bacon J, Watson J, Hwang SW, Dunn J, Guenter D. Positive Spaces Healthy Places Team. Direct and indirect effects of perceived social support on health-related quality of life in persons living with HIV/AIDS. AIDS Care. 2013;25:337-46.

Mengistu N, Hareru HE, Shumye S, Yimer S, Sisay D, Kaso AW, Muche T, Kassaw C, Soboksa NE, Molla W, Molla A, Duko B. Health related quality of life and its association with social support among people living with HIV/AIDS receiving antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Health Qual Life Outcomes. 2022;20:77.

Barger D, Hessamfar M, Neau D, Farbos S, Leleux O, Cazanave C, Rouanes N, Duffau P, Lazaro E, Rispal P, Dabis F, Wittkop L, Bonnet F. Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018–2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study). Sci Rep. 2023;13;16535.

Nobre N, Pereira M, Roine RP, Sintonen H, Sutinen J. Factors associated with the quality of life of people living with HIV in Finland. AIDS Care. 2017;29:1074-8.

Briongos Figuero LS, Luque PB, Martin TP, Sagrado MG, Bouza JME. Assessment of factors influencing health-related quality of life in HIV-infected patients. HIV Med. 2011;12:22-30.

Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992;54:588-601.

Rezaei S, Ahmadi S, Rahmati J, Hosseinifard H, Dehnad A, Aryankhesal A, Shabaninejad H, Ghasemyani S, Alihosseini S, Bragazzi NL, Raoofi S, Kiaee ZM, Ghashghaee A. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Support Palliat Care. 2019;9:404-12.

Fumaz CR, Larrañaga-Eguilegor M, Mayordomo-López S, Gómez-Martínez S, González-García M, Ornellas A, Fuster Ruiz de Apodaca MJ, Remor E, Ballester-Arnal R. Spanish Group for the Quality of Life Improvement in HIV or AIDS. Health-related quality of life of people living with HIV infection in Spain: a gender perspective. AIDS Care. 2019;31:1509-17.

Belak Kovacević S, Vurusić T, Duvancić K, Macek M. Quality of life of HIV-infected persons in Croatia. Coll Antropol. 2006;(30 Suppl 2):79-84.

Perez IR, Lima AODL, del Castillo LS, Bano JR, Ruz MAL, Jimenez AD. No differences in quality of life between men and women undergoing HIV antiretroviral treatment: Impact of demographic, clinical and psychosocial factors. Aids Care. 2009;21:943-52.

Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, Grant I, Woods SP; HIV Neurobehavioral Research Program HNRP Group. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27:5-16.

Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, McCaffrey DF, Fleishman JA, Crystal S, Collins R, Eggan F, Shapiro MF, Bozzette SA. Health-related quality of life in patients with human immunodefciency virus infection in the United States: result from the HIV cost and services utilization study. Am J Med.2000;108:714-22.

Liu H, Zhao M, Ren J, Qi X, Sun H, Qu L, Yan C, Zheng T, Wu Q, Cui Y. Identifying factors associated with depression among men living with HIV/AIDS and undergoing antiretroviral therapy: a crosssectional study in Heilongjiang, China. Health Qual Life Outcomes. 2018;16:190.

Beyene Gebrezgiabher B, Huluf Abraha T, Hailu E, Siyum H, Mebrahtu G, Gidey B, Abay M, Hintsa S, Angesom T. Depression among adult HIV/AIDS patients attending ART clinics at Aksum Town, Aksum, Ethiopia: a cross-sectional study. Depression Res Treat. 2019;2019:3250431.

Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142-5.

Comparison of the Infection Characteristics and Antimicrobial Use Among Patients Hospitalized in the Intensive Care Unit During and After the COVID-19 Pandemic Periods

Abstract

Introduction

Methods

Results

Discussion

Conclusion

Conclusion

References